Frequently Asked Questions

Why is now a good time to invest in the pulmonary care industry and BioSuperior?

New lung pathogens (e.g., COVID variants) and environmental problems (e.g., smoke inhalation from wildfires, military burn pits, etc.) will continue to increase the number of patients with serious lung illness.

In 2021, the number of patients dying from lung disease rivaled deaths due to heart disease and cancer. There is heightened public awareness of these new lung pathogens and environmental problems. Gene therapy is an exciting new treatment modality and has tremendous potential for the treatment of lung disease. And the use of lung surfactant to deliver lung therapeutics is expected to enable breakthroughs in the treatment of serious lung disease.

How will the funds be used and what are your immediate next steps?

We will use the funds over the next year to establish Alveogene, our gene therapy product candidate for the repair of injured lung tissue in Acute Respiratory Distress Syndrome (ARDS) and Acute Lung Injury (ALI). This gene enables lung cells to make a protein that is a key component of the “glue” that naturally adheres neighboring cells to form intact alveoli. We will test the ability of our gene therapy to repair lungs in animal models. In parallel, we will continue working on our prototype synthetic pulmonary surfactant, BioSURF™ through our secured grants.

What is unique about BioSuperior?

Our technology is unique as Alveogene has a unique mechanism of action for the treatment of lung disease. It is not an antiviral or anti-inflammatory therapeutic. Instead, the treatment targets tissue repair as demonstrated by fundamental science and animal studies. And gene has been shown to produce protein for months, much longer than other delivery mechanisms. Since our lung surfactant drug-delivery platform is synthetic, it will be scalable and useful in a number of applications.

All of our drugs are localized to the site of action, thus limiting toxic side effects.

What makes your team especially qualified?

Each member of the BioSuperior team has deep and complementary skills in lung biology, formulation R&D of lung products and product development. We are experienced at leading and working within teams that have developed innovative pharmaceutical products. Some of these have captured more than $1B in annual revenue.

Collectively, we have strong skills in understanding how to develop early-stage biotech companies and a strong network of pulmonologists, thought leaders in respiratory biology research, pharmaceutical scientists and business leaders who provide meaningful perspective and insight.

How will the products be sold and administered, how much will they cost compared to other treatments?

Following regulatory approval, the manufactured product will be sold to specialty pharma and ultimately shipped to hospitals. The drugs will be administered by clinicians (pulmonologists, respiratory therapists, nurses, etc.) by instillation or nebulization directly to the airway. Life-saving drugs administered by gene therapy capture premium revenue. Life-saving drugs delivered with bio-engineered lung surfactant are expected to be much less expensive than the current cost of care for infants suffering from Bronchopulmonary Dysplasia (BPD).

How will eligibility be determined and what will be the process?

BioSuperior will assess safety and efficacy in different patient populations through clinical trials and will seek approval based on this data. We expect our therapeutics to far exceed the current standard of care. This will motivate hospitals and insurance companies to list our drugs on their formularies.